Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Translational Oncology"
DOI: 10.1016/j.tranon.2020.100920
Abstract: Highlights • The glutamine utilization of KRAS-mutant NSCLC is higher than that of KRAS wild-type.• Targeted GLS1 and MEK inhibition enhance antitumor activity in vitro and in vivo.• The therapeutic response can be well identified… read more here.
Keywords: mutant nsclc; inhibition; inhibition glutamine; gls1 mek ... See more keywords